Kalaris Therapeutics (KLRS) Price & Analysis

Compare

371 Followers

KLRS Stock Chart & Stats

$8.26

Market closed

$8.26

Day’s Range― - ―

52-Week Range$2.14 - $12.90

Previous CloseN/A

VolumeN/A

Average Volume (3M)136.22K

Market Cap

$146.62M

Enterprise Value$32.64M

Total Cash (Recent Filing)$77.00M

Total Debt (Recent Filing)$1.54M

Price to Earnings (P/E)―

Beta0.50

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-11.75

Shares Outstanding18,702,417

10 Day Avg. Volume189,046

30 Day Avg. Volume136,224

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)0.40

Price to Sales (P/S)0.00

P/FCF Ratio-0.67

Enterprise Value/Market Cap0.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.02

Forecast

1Y Price Target

$16.67

Price Target Upside101.82% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-3.22

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy SignalsAnalyst notes promising early safety and efficacy signals from the TH103 Phase I study, with improvements in vision and retinal anatomy that suggest potential therapeutic benefit compared with current anti-VEGF options.

Durability PotentialAnalyst highlights preliminary indications of extended durability in some patients treated with TH103, which could translate into fewer retreatments and better treatment adherence if confirmed in larger studies.

Manufacturing And Quality ControlsAnalyst points to the selection of an experienced CDMO and refinement of the purification process to remove impurities as steps that strengthen clinical supply reliability and reduce inflammation risk during development.

Bears Say

Data Interpretability RiskAnalyst cautions that Phase I results in neovascular AMD can be hard to interpret due to the heterogeneous nature of the disease, limiting confidence in how results will generalize to broader patient groups.

Early-stage Validation UncertaintyAnalyst emphasizes that the early-stage status of the data means efficacy and safety profiles remain provisional until confirmed by larger, randomized trials.

Small Sample Size LimitationsAnalyst warns that small patient numbers in early trials reduce statistical reliability of observed effects, increasing the chance that initial signals may not hold in larger studies.

Kalaris Therapeutics News

Kalaris Therapeutics initiated with a Buy at Chardan

Chardan initiated coverage of Kalaris Therapeutics (KLRS) with a Buy rating and $19 price target The firm cites...

18d ago

KLRS

Kalaris Therapeutics price target raised to $26 from $20 at Citizens

Citizens analyst Jonathan Wolleben raised the firm’s price target on Kalaris Therapeutics (KLRS) to $26 from $20 and...

23d ago

KLRS

Kalaris Therapeutics announces $50M private placement

Kalaris Therapeutics (KLRS) announced that it has entered into a securities purchase agreement with a select group of...

23d ago

KLRS

Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27

Based on its current operating plans, Kalaris expects its existing cash, cash equivalents, and short term investments, together...

23d ago

KLRS

Kalaris Therapeutics announces initial data from TH103 trial

Kalaris Therapeutics (KLRS) announced initial data from its Phase 1a single ascending dose trial of TH103, a fully...

23d ago

KLRS

Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending

Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX)...

14d ago

BRO

ANNX

Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on KLRS stock, giving a Buy rating...

18d ago

KLRS

Kalaris Therapeutics Announces Oversubscribed $50 Million Financing

Kalaris Therapeutics ( ($KLRS) ) has issued an announcement. On December 17, 2025, Kalaris Therapeutics announced it had...

23d ago

KLRS

Kalaris Therapeutics Announces Positive Phase 1a Trial Data

Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. Kalaris Therapeutics announced on December 17, 2025, positive initial...

23d ago

KLRS

Kalaris Therapeutics Reports Q3 2025 Financial Progress

Kalaris Therapeutics, Inc. ( ($KLRS) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

KLRS

Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on KLRS stock, giving a Buy rating...

2M ago

KLRS

Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)

“The third quarter marked an important inflection point for Kalaris,” said Andrew Oxtoby, Chief Executive Officer of Kalaris...

2M ago

KLRS

Kalaris Therapeutics Appoints New CFO Matthew Gall

Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall...

2M ago

KLRS

Kalaris Therapeutics appoints Gall as Chief Financial Officer

Kalaris Therapeutics (KLRS) announced the appointment of Matthew Gall, MBA, as Chief Financial Officer. Gall most recently served...

2M ago

KLRS

KLRS FAQ

What was Kalaris Therapeutics’s price range in the past 12 months?

Kalaris Therapeutics lowest stock price was $2.14 and its highest was $12.90 in the past 12 months.

What is Kalaris Therapeutics’s market cap?

Kalaris Therapeutics’s market cap is $146.62M.

When is Kalaris Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kalaris Therapeutics’s earnings last quarter?

Kalaris Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.15.

Is Kalaris Therapeutics overvalued?

According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kalaris Therapeutics pay dividends?

Kalaris Therapeutics does not currently pay dividends.

What is Kalaris Therapeutics’s EPS estimate?

Kalaris Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kalaris Therapeutics have?

Kalaris Therapeutics has 18,702,417 shares outstanding.

What happened to Kalaris Therapeutics’s price movement after its last earnings report?

Kalaris Therapeutics reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went down -2.17%.

Which hedge fund is a major shareholder of Kalaris Therapeutics?

Currently, no hedge funds are holding shares in KLRS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kalaris Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.45%

Trailing 12-Months

Asset Growth

-33.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kalaris Therapeutics

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Kalaris Therapeutics (KLRS) Earnings & Revenues

Historic Earnings Reports

KLRS Stock 12 Month Forecast

Average Price Target

$16.67

▲(101.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","14":"$14","27":"$27","7.5":"$7.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.5,14,20.5,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.45,7.030769230769231,8.611538461538462,10.192307692307693,11.773076923076925,13.353846153846156,14.934615384615384,16.515384615384615,18.096153846153847,19.676923076923078,21.25769230769231,22.83846153846154,24.41923076923077,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.45,6.313076923076924,7.176153846153847,8.03923076923077,8.902307692307694,9.765384615384615,10.62846153846154,11.491538461538465,12.354615384615386,13.21769230769231,14.080769230769231,14.943846153846156,15.80692307692308,{"y":16.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.45,5.415384615384616,5.380769230769231,5.346153846153847,5.311538461538461,5.276923076923077,5.242307692307692,5.207692307692308,5.173076923076923,5.138461538461539,5.1038461538461535,5.069230769230769,5.0346153846153845,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.63,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.93,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >